Johnson & Johnson Raises Price Target to $227
On December 5, Guggenheim raised Johnson & Johnson's price target to $227 from $206 and kept a Buy rating, citing additional upside into 2026. J&J is reorganizing by spinning off DePuy Synthes within 18 to 24 months, after earlier spinning off Kenvue, and acquiring Halda Therapeutics for $3.05 billion to bolster its oncology portfolio. These moves refocus the company on higher-growth pharmaceuticals amid competitive pressure.
Key Points
- 1Guggenheim raises J&J price target to $227 and maintains a Buy rating on December 5
- 2Company spins off DePuy Synthes and previously Kenvue to concentrate on higher-growth pharmaceuticals
- 3Acquires Halda Therapeutics for $3.05B to strengthen oncology portfolio amid competitive pressure
Scoring Rationale
Official analyst upgrade and strategic acquisition indicate meaningful repositioning, but limited AI/DS relevance reduces broader portal impact.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
